TMSS Medical College Journal

Background: The burden of Chronic Kidney Disease (CKD) is increasing rapidly worldwide and has become a major health problem. Patients with CKD are at higher risk for cardiovascular disease (CVD) than patients in the general population. Lipid disorders are recognized risk factors for CVD. Objectives: To observe the pattern of lipid profile in non-dialyzed CKD patients. Methods: This comparative study was carried out in the Department of Biochemistry, Dhaka Medical College, Dhaka during the period of July 2013 to June 2014. A total number of 100 subjects of both sexes were selected with age ranging from 18 to 60 years according to selection criteria. Among them, 50 CKD patients were included in group I and 50 health subjects in group IL. Serum lipid profile among the groups were assessed and statistically compared. For statistical analysis Student t-test was performed using SPSS for windows version 16. Results: The mean (£SD) of serum TG level was significantly higher in CKD patients (209.12 + 38.20) than healthy control group (140.44 + 37.99) and the mean (+SD) of serum HDL level was significantly lower in CKD patients (30.50 + 10.77) than healthy control group (39.94 = 9.26). Conclusion: Dyslipidemia is more common in non-dialyzed CKD patients.

Chronic kidney disease (CKD) is a major public health problem worldwide. According to Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney Foundation (NKF), CKD is either kidney damage for = 3 months, as defined by structural or functional abnormalities of Kidney, with or without decreased glomerular filtration rate (GFR) or GFR < 60 ml/min/1.73 m* for > 3 months, with or without kidney damage”. The incidence and prevalence of chronic kidney disease (CKD) are increasing worldwide. According to the 1999 — 2004 National Health and Nutritional Survey (NHANES), the prevalence of CKD in the US population is 15.3%". In the developing countries, the awareness and burden of CKD on society has been high lightened during last decade. Incidence of CKD in Bangladesh is 19%. The prevalence of CKD is increasing worldwide as a consequence of hypertension and diabetes mellitus’. Increase in prevalence of CKD is an alarming condition. Because it is an irreversible condition and is associated with increased health hazards’. A patient with CKD leads to many complications over a period of time, the most common include cardiovascular, cerebrovascular and peripheral vascular disease’. The incidence of cardiovascular disease (CVD) is also high in patients with CKD. CVD is the leading cause of death among the patients with chronic kidney disease’. There is growing evidence that cardiovascular damage begins as soon as the kidney loses function and increases in severity during the progression of kidney discasc’. Dyslipidemia independently or in combination with clevated blood pressure can cause deterioration in renal function. Abnormalities in lipid metabolism and dyslipidemia are known to contribute to glomerulo-sclerosis and are common in renal disease. The impact of lipid abnormalities on renal function has been evaluated in various studies’. Abnormal lipid profiles start to appear soon after renal function begins to deteriorate’. Dyslipidemia has been established as a well known traditional risk factor for CVD in the general population as well as in CKD patient. CKD patients usually display elevated triglyceride (TG) and reduced serum high density lipoprotein-cholesterol (HDL-C). Serum total cholesterol and low density lipoprotein- cholesterol (LDL-C) levels usually remain within normal limits". The National Kidney Foundation (NFK), Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines on the management of dyslipidemia in CKD patients with 1) Fasting triglycerides >500mg/dl (5.65 mmol/L); 2) LDL-C>100mg/dl (2.59 mmol/L) and 3) non-HDL cholesterol >130mg/dl (3.36 mmol/L) should be considered for treatment to reduce the cardiovascular complications in these patients’. Keeping in view, the mortality associated with CVD and the association of lipid profile levels with CVD in CKD patients, we have planned to study the serum lipid profile of CKD patients.